Equities

Milestone Pharmaceuticals Inc

MIST:NSQ

Milestone Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.71
  • Today's Change-0.04 / -2.29%
  • Shares traded87.94k
  • 1 Year change-60.23%
  • Beta1.7562
Data delayed at least 15 minutes, as of May 24 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

  • Revenue in USD (TTM)0.00
  • Net income in USD-55.09m
  • Incorporated2003
  • Employees47.00
  • Location
    Milestone Pharmaceuticals Inc420-1111 boul. Dr.-Frederik-PhilipsMONTREAL H4M 2X6CanadaCAN
  • Phone+1 (514) 336-0444
  • Fax+1 (514) 336-0444
  • Websitehttps://www.milestonepharma.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Angion Biomedica Corp0.00-38.99m86.37m32.00--17.65-----6.63-6.630.000.47650.00----0.00-117.72-105.91-133.85-331.69-------712.81----0.00---100.00--9.31------
Gritstone bio Inc15.65m-144.89m87.03m231.00--5.63--5.56-1.57-1.570.170.14230.0901--40.5367,727.27-83.47-48.08-97.70-55.18-----926.13-573.71---554.880.7428---18.0568.96-15.71---4.19--
Allovir Inc0.00-179.53m87.06m112.00--0.7221-----1.65-1.650.001.050.00----0.00-92.50-52.85-100.98-57.72-------378,613.90----0.00-------12.87------
Precision BioSciences Inc57.53m-19.99m88.23m109.00--2.37--1.53-5.50-7.4113.765.380.2956--47.10527,807.30-10.27-35.35-12.94-44.22-----34.74-147.50----0.3764--94.1534.9641.67---32.01--
SCYNEXIS Inc140.39m101.33m88.78m29.001.171.20--0.63242.012.012.891.961.49--136.304,840,862.00107.48-30.02175.37-36.3588.97--72.18-86.76--193.810.1433--2,652.72252.64206.74------
Leap Therapeutics Inc0.00-53.37m91.07m54.00--1.29-----2.39-2.390.001.850.00----0.00-64.88-80.06-74.25-95.03-------7,900.37----0.00-------49.12------
Milestone Pharmaceuticals Inc0.00-55.09m91.08m47.00--2.28-----1.25-1.250.000.74980.00----0.00-53.21-48.44-56.51-51.56-------1,267.25----0.5592---80.00---2.22--86.23--
Eton Pharmaceuticals Inc34.30m913.00k91.97m30.00105.825.9449.632.680.03380.03381.330.60311.258.419.641,143,467.003.34-46.225.72-58.2066.2472.162.66-76.861.43--0.2447--48.90--89.62--26.85--
Relmada Therapeutics Inc0.00-94.30m92.03m20.00--1.28-----3.13-3.130.002.390.00----0.00-85.74---95.48--------------0.00------37.09------
Zhong Yuan Bio-Technology Holdings Ltd2.49m232.02k92.64m35.00410.98365.90--37.150.0128-0.01760.13950.01430.8583-1.613.2571,253.436.49--19.10--106.30--7.57--0.83092.530.8593---28.60---148.37------
Armata Pharmaceuticals Inc4.70m-79.58m94.73m66.00------20.16-2.20-2.200.1302-1.560.041--3.1671,196.97-69.46-59.78-235.17-72.70-----1,693.47-1,113.72---1.111.75---17.77---87.03--184.10--
Oramed Pharmaceuticals, Inc.674.00k10.46m95.07m15.009.410.5699.10141.060.24880.24880.01654.110.0037----44,933.335.63--6.27------1,518.25------0.162---50.43--115.11------
Assertio Holdings Inc142.05m-332.97m95.12m53.00--0.7072--0.6697-3.95-3.951.661.410.40811.193.192,680,208.00-95.65-21.51-130.77-32.0576.9688.68-234.40-62.101.45--0.2231---2.67-13.38-402.80---28.25--
LifeVantage Corp205.45m3.60m95.64m248.0026.933.5713.150.46550.27960.279616.012.113.202.5391.56828,443.605.6011.658.5118.9279.3282.201.753.421.01--0.005.233.410.9838-18.59-18.77-7.98--
Data as of May 24 2024. Currency figures normalised to Milestone Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

44.47%Per cent of shares held by top holders
HolderShares% Held
BlackRock Financial Management, Inc.as of 31 Mar 20244.71m8.86%
RTW Investments LPas of 31 Mar 20243.26m6.13%
Millennium Management LLCas of 31 Mar 20242.86m5.37%
Alta Fundamental Advisers LLCas of 31 Mar 20242.37m4.46%
Lion Point Capital LPas of 31 Mar 20242.30m4.33%
Citadel Advisors LLCas of 31 Mar 20242.25m4.24%
Nantahala Capital Management LLCas of 31 Mar 20241.75m3.29%
Stonepine Capital Management LLCas of 31 Mar 20241.46m2.75%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 20241.35m2.55%
Bleichroeder LPas of 31 Mar 20241.33m2.50%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.